Tag: product development

5G leader adds industry veterans Lawrence Hau as Chief Supply Chain Officer, reinforcing its command of global supply chain excellence, and Zack Kowalski as Senior Vice President of Business Development, to lead the company’s channel expansion strategy

Key sectors in the white biotechnology market include biofuels, biochemicals, industrial enzymes, and biomaterials, with new fields like bioremediation emerging. Advances in synthetic biology and digital tools such as machine learning are accelerating product development and market entry, driving growth from niche to large-scale industrial applications. The market is in a growth phase, buoyed by rising demand for renewable resources but challenged by high initial investment costs. Notable players include Novozymes, DuPont, BASF, and Evonik. North America is a key region, driven by government initiatives for renewable resources.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2025 (the “Grant Date”), ORIC granted a total of 35,000 non-qualified stock options and 5,800 restricted stock units to two new non-executive employees who began their employment with ORIC in July 2025.

Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.¹ Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.